Blog

The latest thoughts from Medicines Law & Policy partners.

Humiragate: AbbVie’s desperate attempts to keep its monopoly

A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...

We need a Global Vaccines Taskforce, not just a British or European one

The European Commission has been heavily criticised for its performance over Covid-19 vaccine supply to European Union Member States. Despite the urgency of the...

Dolutegravir Patent Licences Can Provide Access To All

This year the World Health Organization (WHO) added dolutegravir, an antiretroviral medicine for the treatment of HIV infection, to its Model List of Essential...

The Expanding Reach of the European Patent Office. Good for Health?

The European Patent Office (EPO) is tasked with the examination of patent applications and the granting of patents when these applications meet the patentability...

CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...

Medicines Law & Policy welcomes WHO’s Solidarity Call to Action to realise equitable global...

The World Health Organization today with Costa Rica launched the "COVID-19 Technology Access Pool (C-TAP)" to ensure that knowledge, data and intellectual property are...

WHO Fair Pricing Forum: Watching for Drug Industry Accountability

by Katrina Perehudoff and Jennifer Sellin Expensive medicines are a ubiquitous challenge from which no government is immune. Excessive price hikes are an urgent human...

Dutch Health Care Institute Says No to Medicines Pirate

It seems the Dutch health care system and health care professionals are fed up with the abuse of the orphan medicines regulation, which is...

Modifier la législation européenne pour mettre en œuvre la licence d’office en France

Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. » L’augmentation croissante du prix...

Dutch Court Orders AstraZeneca to Pay Damages in Patent Evergreening Case

Today the Dutch court made a long-awaited ruling in the patent evergreening case of health insurance company Menzis versus AstraZeneca. It found that AstraZeneca...